Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy

Pierfrancesco Franco, Andrea Riccardo Filippi, Patrizia Ciammella, Angela Botticella, Agnieszka Namysl-Kaletka, Alberto de Crescenzo, Corrado Tarella, Umberto Ricardi

Research output: Contribution to journalArticle

Abstract

Primary gastrointestinal lymphoma (PGL) is known to account for 40% of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4% to 12% of all NHLs. The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalActa Gastro-Enterologica Belgica
Volume74
Issue number2
Publication statusPublished - Jun 2011

Fingerprint

Follicular Lymphoma
Radio
Immunotherapy
Non-Hodgkin's Lymphoma
Surface Antigens
Ileum
Duodenum
Small Intestine
Lymphoma
B-Lymphocytes
Radiotherapy
Therapeutics
Immunoglobulin G
Bone Marrow
Antibodies
Incidence

Keywords

  • Duodenal
  • Follicular
  • Lymphoma
  • Radiotherapy
  • Rituximab

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Franco, P., Filippi, A. R., Ciammella, P., Botticella, A., Namysl-Kaletka, A., de Crescenzo, A., ... Ricardi, U. (2011). Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy. Acta Gastro-Enterologica Belgica, 74(2), 337-342.

Primary duodenal follicular lymphoma : 6-years complete remission after combined radio-immunotherapy. / Franco, Pierfrancesco; Filippi, Andrea Riccardo; Ciammella, Patrizia; Botticella, Angela; Namysl-Kaletka, Agnieszka; de Crescenzo, Alberto; Tarella, Corrado; Ricardi, Umberto.

In: Acta Gastro-Enterologica Belgica, Vol. 74, No. 2, 06.2011, p. 337-342.

Research output: Contribution to journalArticle

Franco, P, Filippi, AR, Ciammella, P, Botticella, A, Namysl-Kaletka, A, de Crescenzo, A, Tarella, C & Ricardi, U 2011, 'Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy', Acta Gastro-Enterologica Belgica, vol. 74, no. 2, pp. 337-342.
Franco P, Filippi AR, Ciammella P, Botticella A, Namysl-Kaletka A, de Crescenzo A et al. Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy. Acta Gastro-Enterologica Belgica. 2011 Jun;74(2):337-342.
Franco, Pierfrancesco ; Filippi, Andrea Riccardo ; Ciammella, Patrizia ; Botticella, Angela ; Namysl-Kaletka, Agnieszka ; de Crescenzo, Alberto ; Tarella, Corrado ; Ricardi, Umberto. / Primary duodenal follicular lymphoma : 6-years complete remission after combined radio-immunotherapy. In: Acta Gastro-Enterologica Belgica. 2011 ; Vol. 74, No. 2. pp. 337-342.
@article{2ae5d48e624d4832a3f9d155a0603ba0,
title = "Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy",
abstract = "Primary gastrointestinal lymphoma (PGL) is known to account for 40{\%} of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4{\%} to 12{\%} of all NHLs. The small intestine is the site of presentation in 20-30{\%} of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity.",
keywords = "Duodenal, Follicular, Lymphoma, Radiotherapy, Rituximab",
author = "Pierfrancesco Franco and Filippi, {Andrea Riccardo} and Patrizia Ciammella and Angela Botticella and Agnieszka Namysl-Kaletka and {de Crescenzo}, Alberto and Corrado Tarella and Umberto Ricardi",
year = "2011",
month = "6",
language = "English",
volume = "74",
pages = "337--342",
journal = "Acta Gastro-Enterologica Belgica",
issn = "0001-5644",
publisher = "Universa Press",
number = "2",

}

TY - JOUR

T1 - Primary duodenal follicular lymphoma

T2 - 6-years complete remission after combined radio-immunotherapy

AU - Franco, Pierfrancesco

AU - Filippi, Andrea Riccardo

AU - Ciammella, Patrizia

AU - Botticella, Angela

AU - Namysl-Kaletka, Agnieszka

AU - de Crescenzo, Alberto

AU - Tarella, Corrado

AU - Ricardi, Umberto

PY - 2011/6

Y1 - 2011/6

N2 - Primary gastrointestinal lymphoma (PGL) is known to account for 40% of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4% to 12% of all NHLs. The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity.

AB - Primary gastrointestinal lymphoma (PGL) is known to account for 40% of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4% to 12% of all NHLs. The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity.

KW - Duodenal

KW - Follicular

KW - Lymphoma

KW - Radiotherapy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=80052877809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052877809&partnerID=8YFLogxK

M3 - Article

C2 - 21861321

AN - SCOPUS:80052877809

VL - 74

SP - 337

EP - 342

JO - Acta Gastro-Enterologica Belgica

JF - Acta Gastro-Enterologica Belgica

SN - 0001-5644

IS - 2

ER -